Mölndal, Sweden - March 26, 2024 -Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has entered a commercial agreement with AMI Technologies, a leading local medical device distributor, to introduce the OPRATM Implant System in Israel.

As part of Integrum's efforts to expand the availability of the OPRA™ Implant System to new geographical markets, the company has as of today started a collaboration in Israel with AMI Technologies (www.ami.co.il).

"The collaboration with AMI Technologies secures a swift launch of OPRA™ Implant System in Israel and shortens the distance between us and patients needing reconstructive surgery. We see a large need for our innovative products in the region and hope we can help improve the quality of life for amputees," says Rickard Brånemark, CEO of Integrum.

For more information, please contact:

Rickard Brånemark, CEO
Phone: +46 (0) 70 846 10 61
E-mail: rickard.branemark@integrum.se

Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail: Jorgen.svanstrom@integrum.se

Certified Adviser

Carnegie Investment Bank AB (publ) is Certified Adviser.

ABOUT INTEGRUM

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.

https://news.cision.com/integrum-ab/r/integrum-expands-its-product-offering-into-the-israeli-market,c3952047

https://mb.cision.com/Public/17531/3952047/a8a6b8676b575e64.pdf

(c) 2024 Cision. All rights reserved., source Press Releases - English